Mechanisms of recurrence of Ta/T1 bladder cancer

Annals of the Royal College of Surgeons of England

Volumn 92, Issue 6, 2010, Pages 519-524

  Bryan, Richard T ^a   Collins, Stuart I ^a   Daykin, Mark C ^b   Zeegers, Maurice P ^a,c   Cheng, K K ^a   Wallace, D Michael A ^d   Sole, Graham M ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HEREFORD COUNTY HOSPITAL   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Mechanisms; Recurrence

Indexed keywords

ARTICLE; BLADDER TUMOR; CANCER STAGING; EPIDEMIOLOGY; HUMAN; PATHOLOGY; TIME; TUMOR RECURRENCE;

EPIDEMIOLOGIC METHODS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 77957911070     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588410X12664192076935     Document Type: Article

References (30)

1. Office for National Statistics. Report: Cancer incidence and mortality in the United Kingdom and constituent countries, 2003-05. Health Statistics Quarterly 2008; 40: 1-91.
2. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-42.
3. Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997; 14: 98-108.
4. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackerman R, Vögeli T. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170: 433-7.
5. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-77.
6. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30.
7. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33: 828-41.
8. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DMA. Molecular pathways in bladder cancer. Part 2. BJU Int 2005; 95: 491-6.
9. Sidransky D, Frost P, Von Eschenbach A, Oyasu Y, Preisinger A, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992; 326: 737-40.
10. Tsai YC, Simoneau AR, Spruck CH, Nichols PW, Steven K, Buckley JD et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol 1995; 153: 1697-700.
11. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998; 58: 5835-41.
12. Simon R, Eltze E, Schafer KL, Burger H, Semjonow A, Hertle L et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumour cells. Cancer Res 2001; 61: 355-62.
13. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE. Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol 2004; 171: 419-25.
14. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 2001; 20: 4910-5.
15. Knowles MA. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008; 13: 287-97.
16. Kondas J, Kiss L, Hatar A, Kiss A, Lukacs T, Szeldeli P et al. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study. Int Urol Nephrol 1999; 31: 451-6.
17. Weldon TE, Soloway MS. Susceptibility of normal urothelium to neoplastic cellular implantation. Urology 1975; 5: 824-7.
18. Soloway MS. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 1977; 37: 2918-29.
19. Schips L, Augustin H, Zigeuner R, Galle G, Habermann H, Trummer H et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002; 59: 220-3.
20. Riedl CR, Daniltchenko D, Koenig F, Simak, R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001; 165: 1121-3.
21. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumours. J Urol 2002; 168: 67-71.
22. Tolley DA, Parmar MKB, Grigor KM, Lallemand G, The Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996; 155: 1233-7.
23. Solsona E, Iborra I, Ricos JV, Monros J, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol 1999; 161: 1120-3.
24. Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999; 86: 1818-26.
25. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder. Anticancer Res 2001; 21: 765-9.
26. van der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999; 35: 267-71.
27. May F, Treiber U, Hartung R, Schwaibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol 2003; 44: 47-50.
28. Bryan RT, Billingham LJ, Wallace DMA. Narrow band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int 2008; 101: 702-5.
29. Wilby D, Thomas K, Ray E, Chappell B, O'Brien T. Bladder cancer: new TUR techniques. World J Urol 2009; 27: 309-12.
30. Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS et al. The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int 2010; 105: 784-8.